Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

Adjuvant nivolumab (Opdivo) generated a long-term efficacy benefit compared with ipilimumab (Yervoy) for the treatment of patients with resected stage IIIB to IIIC or IV melanoma, according to final data from the phase 3 CheckMate 238 trial…